Titlebook: Dyslipidemias in Kidney Disease; Adrian Covic,Mehmet Kanbay,Edgar V. Lerma Book 2014 Springer Science+Business Media New York 2014 Dialysi

積習(xí)難改

The CKD Patient with Dyslipidemia,cation to small and dense low-density lipoproteins, which render the particles more atherogenic. These abnormalities contribute to the development of cardiovascular events, and they may worsen the progression of CKD..In this chapter we will briefly discuss the peculiar quantitative and qualitative a

Ledger

Review of Clinical Trials Pertaining to Dyslipidemias in CKD, patients with a kidney transplant clearly benefit from statin therapy. In summary, available evidence clearly supports the use of statins in CKD patients not on dialysis and in those with a kidney transplant, in particular in the presence of concomitant CV risk factors or established CV disease.

反抗者

Dyslipidemia in Dialysis,compared with their HD counterparts. Modifications in some parameters of HD or PD along with pharmacologic therapy, mainly statins, constitute the current therapeutic armamentarium against dyslipidemia in dialysis patients. Future randomized controlled trials taking into account the particular chara

cushion

Dyslipidemias in the Pediatric Chronic Kidney Disease Patient,ategories of pediatric patients are discussed in light of the limited number of studies in this population. Concerning the differences between the disease profile of adults and children, adult data could not be directly translated in children. Thus, prospective investigations regarding the clinical

脆弱吧

Apheresis Methods in Hyperlipidemias,hese options had important morbidity attached to each other, selective low-density lipoprotein (LDL) apheresis has been considered as the most promising strategy in the treatment era. This chapter will focus on the techniques and outcomes of LDL-apheresis strategies on FH that could significantly im

aggrieve